NxThera Inc.
Feds slap former Acclarent execs with fraud charges
Federal prosecutors last week leveled conspiracy and fraud charges against 2 former executives of Acclarent for an alleged off-label marketing scheme for the Relieva Stratus microflow spacer.
RIP former Evalve CEO Powell | Personnel Moves
More changes at Hologic as it axes administrative chief Casey | Personnel Moves
Medtech funding for the week of Mar. 3, 2014
EarLens pulls in $36M for infrared hearing aid
March 3, 2014 by Brad Perriello
EarLens said it raised some $36 million in an equity round for the hearing aid technology it’s developing that uses infrared rather than sound waves.
NxThera closes $20M Series C round
NxThera said it closed a $20 million Series C round that topped its initial $18 million target.
Maple Grove, Minn.-based NxThera won CE Mark approval in the European Union last August for its Rezūm prostate device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia.
NxThera closes $18M Series C, wins CE Mark for Rezum prostate device
NxThera said it closed on a Series C round worth $18.2 million and won CE Mark approval for its Rezum treatment for benign prostatic hyperplasia.
Maple Grove, Minn.-based NxThera’s device uses steam to reduce the size of the prostate to relieve urinary symptoms from BPH, according to NxThera’s website.
Medtech funding: NxThera raises $3.5 million
NxThera reported raising $3.5 million in an April 4 regulatory filing:
Company: NxThera
Raise: $3.5 million
Security: Debt; Options/Warrants
Investors: 17
Sales Commission: $0
Finders’ Fees:$0
Entegrion lands $43.7 million DOD deal | Funding Roundup
Entegrion landed a $43.7 million dollar contract with the Dept. of Defense for its Resusix proprietary dehydrated pathogen-inactivated human plasma.
Resusix holds promise as a substitute for fresh frozen plasma in certain situations. The Defense Dept. contract will fund Resusix’s development through Phase III clinical trials and biological license application.
Thermalin Diabetes snaps up $2.9 million in A round | Funding roundup
Startup Thermalin Diabetes LLC closed a $2.85 million Series A investment round.
The Cleveland-based synthetic insulin developer plans to use the funding to step up production of its insulin analogs — new proteins engineered to act like insulin in the body — and continue preclinical testing.
NxThera’s mystery backer is American Medical Systems
Word is out about the identity of the corporate partner NxThera CEO Robert Paulson mentioned last week: American Medical Systems Inc. (NSDQ:AMMD).
AMS specializes in medical devices related to pelvic health. NxThera is developing a thermal vapor prostate treatment that involves the same area of the body where American Medical Systems’ expertise lies.
